Pharma Equity Group A/S Cl A (PEG) — Working Capital to Net Assets Ratio
Pharma Equity Group A/S Cl A (PEG) has a Working Capital to Net Assets ratio of 115.6% as of December 2025. Working capital of Dkr29.43 Million (current assets of Dkr38.26 Million minus current liabilities of Dkr8.83 Million) is measured against net assets of Dkr25.47 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Pharma Equity Group A/S Cl A's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Pharma Equity Group A/S Cl A Working Capital to Net Assets (2008–2025)
This chart shows how Pharma Equity Group A/S Cl A's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2008 to 2025. As of December 2025, the ratio stands at 115.6%, reflecting working capital of Dkr29.43 Million against net assets of Dkr25.47 Million DKK. Check Pharma Equity Group A/S Cl A tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Pharma Equity Group A/S Cl A (2008–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Pharma Equity Group A/S Cl A from 2008 to 2025, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Pharma Equity Group A/S Cl A stock valuation.
| Year | WC/NA Ratio | Working Capital (DKK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 115.6% | Dkr29.43 Million | Dkr25.47 Million | Dkr38.26 Million | Dkr8.83 Million | ▼ -0.5 pp |
| 2024 | 116.0% | Dkr56.70 Million | Dkr48.88 Million | Dkr65.33 Million | Dkr8.63 Million | ▼ -13.8 pp |
| 2023 | 129.9% | Dkr32.90 Million | Dkr25.33 Million | Dkr67.23 Million | Dkr34.33 Million | ▲ +29.9 pp |
| 2022 | 100.0% | Dkr46.05 Million | Dkr46.05 Million | Dkr71.07 Million | Dkr25.03 Million | ▲ +133.7 pp |
| 2021 | -33.7% | Dkr-14.35 Million | Dkr42.57 Million | Dkr145.00K | Dkr14.50 Million | ▲ +34.0 pp |
| 2020 | -67.7% | Dkr-23.22 Million | Dkr34.28 Million | Dkr82.00K | Dkr23.30 Million | ▼ -177.7 pp |
| 2019 | 110.0% | Dkr73.87 Million | Dkr67.16 Million | Dkr79.11 Million | Dkr5.24 Million | ▲ +12.2 pp |
| 2018 | 97.8% | Dkr75.85 Million | Dkr77.57 Million | Dkr79.11 Million | Dkr3.27 Million | ▼ -2.2 pp |
| 2017 | 100.0% | Dkr85.09 Million | Dkr85.09 Million | Dkr86.30 Million | Dkr1.21 Million | ▲ +0.0 pp |
| 2016 | 100.0% | Dkr96.78 Million | Dkr96.78 Million | Dkr125.75 Million | Dkr28.98 Million | ▲ +107.1 pp |
| 2015 | -7.1% | Dkr-7.11 Million | Dkr99.53 Million | Dkr2.70 Million | Dkr9.81 Million | ▼ -3.9 pp |
| 2014 | -3.3% | Dkr-3.22 Million | Dkr97.95 Million | Dkr721.00K | Dkr3.94 Million | ▼ -156.5 pp |
| 2013 | 153.2% | Dkr-161.57 Million | Dkr-105.44 Million | Dkr44.83 Million | Dkr206.40 Million | ▼ -17.0 pp |
| 2012 | 170.3% | Dkr61.96 Million | Dkr36.39 Million | Dkr89.42 Million | Dkr27.46 Million | ▲ +195.1 pp |
| 2011 | -24.8% | Dkr-19.76 Million | Dkr79.67 Million | Dkr82.38 Million | Dkr102.14 Million | ▼ -82.7 pp |
| 2010 | 57.9% | Dkr30.74 Million | Dkr53.06 Million | Dkr41.75 Million | Dkr11.01 Million | ▼ -32.6 pp |
| 2009 | 90.5% | Dkr48.40 Million | Dkr53.47 Million | Dkr60.58 Million | Dkr12.18 Million | ▲ +76.9 pp |
| 2008 | 13.6% | Dkr7.66 Million | Dkr56.25 Million | Dkr213.07 Million | Dkr205.42 Million | — |